People: Orchid Cellmark Inc. (ORCH.O)
ORCH.O on Consolidated Issue listed on NASDAQ Global Market
1.60USD
9 Feb 2010
1.60USD
9 Feb 2010
Price Change (% chg)
$-0.07 (-4.19%)
$-0.07 (-4.19%)
Prev Close
$1.60
$1.60
Open
--
--
Day's High
$1.68
$1.68
Day's Low
$1.60
$1.60
Volume
11,905
11,905
Avg. Vol
9,691
9,691
52-wk High
$2.20
$2.20
52-wk Low
$0.50
$0.50
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Beery, James | 68 | 2009 | Chairman of the Board |
| Bologna, Thomas | 61 | 2006 | President, Chief Executive Officer, Director |
| Smith, James | 59 | 2007 | Chief Financial Officer, Vice President |
| Thomas, William | 50 | 2007 | Vice President, General Counsel |
| Boschwitz, Jeffrey | 42 | 2008 | Vice President - North America Marketing and Sales |
| Hecht, Sidney | 65 | 1995 | Director |
| Noonan, Kenneth | 61 | 2001 | Director |
| Williams, Nicole | 65 | 2002 | Director |
| Hart, James | 2010 | Director |
Biographies
| Name | Description |
|---|---|
| Beery, James | Mr. James R. Beery has served as Director since April 2004 and as Chairman of the Board of Orchid Cellmark Inc since August 2009. From March 2002 to the present, Mr. Beery has served as Senior Of Counsel to Covington & Burling, an international law firm based in Washington, D.C. From December 2000 until his retirement in June 2001, Mr. Beery served as Senior Vice President and General Counsel of GlaxoSmithKline PLC, a UK-based global pharmaceutical company. From 1993 until the formation of the merged company GlaxoSmithKline in December 2000, Mr. Beery served as Senior Vice President, General Counsel and Secretary of SmithKline Beecham PLC. He is currently a director of Martek Biosciences Corporation, deCODE Genetics, Inc., the London Centre for the International Education of Students and Inion, Oy, and is a member of the Board of Visitors of Stanford Law School. Mr. Beery received his J.D. from Stanford Law School and A.B. in Physical Sciences from Harvard College. |
| Bologna, Thomas | Mr. Thomas A. Bologna serves as President and Chief Executive Officer and Director of Orchid Cellmark Inc. since April 2006. From 2004 to 2005, Mr. Bologna was Chief Executive Officer, President and a director of Quorex Pharmaceuticals, Inc. a pre-clinical stage anti-infective company. Mr. Bologna was Chief Executive Officer, President and a director of Ostex International, Inc. which developed, manufactured and marketed innovative products for the management of osteoporosis, from 1997 to 2003, and in 1999 he was also appointed Chairman of the Board. From 1996 to 1997, Mr. Bologna was a principal at Healthcare Venture Associates, a consulting firm. From 1994 to 1996, Mr. Bologna was Chief Executive Officer, President and a director of Scriptgen Pharmaceuticals, Inc., a biotechnology company with proprietary drug screening technology that developed orally active drugs to regulate gene expression, and from 1987 to 1994, Mr. Bologna was Chief Executive Officer, President and a director of Gen-Probe Incorporated, a biotechnology company commercializing genetic-probe-based technology for diagnostic and therapeutic applications, and in 1992 he was also appointed Chairman of the Board. Prior to Gen-Probe, Mr. Bologna held several senior level positions with Becton, Dickinson and Company and Warner-Lambert Company. At Becton, Dickinson and Company, he served as President of the Diagnostic Instrument Systems Division, President of the Johnston Laboratories Division, and Vice President and General Manager of the Hynson, Wescott & Dunning biotechnology unit. At Warner-Lambert Company, he served as a Vice President responsible for the marketing, sales and research and development functions, as well as the Asia/Pacific profit center for the Scientific Instrument Division. Mr. Bologna received an M.B.A. and a B.S. from New York University. |
| Smith, James | Mr. James F. Smith serves as Vice President and Chief Financial Officer of Orchid Cellmark Inc. since October 2007. Mr. Smith was most recently Executive Vice President and Chief Financial Officer of Aphton Corporation, a biotechnology company that developed cancer immunotherapies, from August 2004 to 2007. Prior to joining Aphton, he served as Vice President and Global Controller of Ansell (Healthcare) Ltd., a manufacturer of healthcare-related barrier protection products, from 2001 to 2004. Prior to that, Mr. Smith held senior finance/accounting positions for Wyeth and American Cyanamid Company. After graduating from Quinnipiac University with a degree in accounting, Mr. Smith started his accounting career at PricewaterhouseCoopers. He is licensed as a certified public accountant. |
| Thomas, William | Mr. William J. Thomas serves as Vice President and General Counsel of Orchid Cellmark Inc. since November 2007. Mr. Thomas was formerly Senior Vice President and General Counsel for Cytogen Corporation, a specialty pharmaceutical company that commercializes oncology products, from August 2004 to November 2007. Prior to joining Cytogen, Mr. Thomas was a senior partner with the law firm of Wilmer Cutler Pickering Hale and Dorr LLP from January 2000 to August 2004. Previously, he was a partner at the law firm Buchanan Ingersoll P.C. Mr. Thomas has more than 20 years of experience in the areas of general corporate issues, public offerings, mergers and acquisitions, securities law compliance, licensing and managing intellectual property. Mr. Thomas received a J.D. degree from Fordham University School of Law and a B.A. degree in Political Science from Rutgers University. |
| Boschwitz, Jeffrey | Mr. Jeffrey S. Boschwitz, Ph.D., serves as Vice President, North America Marketing and Sales of Orchid Cellmark Inc. since May 2008. Dr. Boschwitz has over 12 years experience in the diagnostics and pharmaceutical industries. Before joining the company, he was Director of Marketing Planning and Analysis at Quest Diagnostics where he was responsible for development of the physician business marketing plan and optimizing sales force effectiveness of plan execution. Previously, Dr. Boschwitz was a Principal in Booz Allen Hamilton’s health care practice with a focus on growth and operations projects for the diagnostics and pharmaceutical industries. Earlier in his career, he was a Project Manager for Plan A Consulting where he led projects to optimize the value of pharmaceutical and biotechnology company new product pipelines. Dr. Boschwitz received a B.S. in Biology and Ph.D. in Immunology from Cornell University and completed his Post-Doctoral work at Stanford University. |
| Hecht, Sidney | Mr. Sidney M. Hecht, Ph.D., has served as a member of the Board of Directors of Orchid Cellmark Inc. since 1995. Dr. Hecht is Director of the Center for Bioenergetics in the Biodesign Institute and Professor of Chemistry at Arizona State University. He was the John W. Mallet Professor of Chemistry and Professor of Biology at the University of Virginia from 1978 until 2008. From 1981 to 1987, Dr. Hecht held concurrent appointments first as Vice President, Preclinical Research and Development, and then Vice President, Chemical Research and Development at SmithKline & French Laboratories, where he was appointed a Distinguished Fellow. From 1971 to 1979, he was assistant professor and then associate professor of chemistry at the Massachusetts Institute of Technology. Dr. Hecht received his B.A. in Chemistry from the University of Rochester and his Ph.D. in Chemistry from the University of Illinois. He serves on the board of directors of Pinnacle Pharmaceuticals, Inc. |
| Noonan, Kenneth | Mr. Kenneth Daniel Noonan, Ph.D., serves as Director of Orchid Cellmark Inc. since December 2001. He has been a partner at London-based L.E.K. Consulting LLP since November 2001, where he focuses on the European life sciences industry. Prior to joining L.E.K., Dr. Noonan was the senior Vice President of Corporate Development for Applera Corporation from 2000 to 2001 where he had corporate responsibility for strategy and transactions. Dr. Noonan has significant experience consulting to European life sciences companies first as the founder and managing director of The Wilkerson Group Ltd. (a specialist life science consultancy), and subsequently as Head of Booz-Allen and Hamilton’s European pharmaceutical practice from 1995 to 2000. Prior to becoming a consultant, Dr. Noonan was the Vice President of Technology Assessment and Business Development for CooperTechnicon Corp. and prior to that he was Director of Research and Development for BD Microbiology Systems. Dr. Noonan sits on a variety of public and private boards of directors, including TyraTech Inc., Intercept Pharmaceuticals, Inc. and Premier Research Group Ltd. Dr. Noonan’s academic credentials include a Ph.D. in Biochemistry from Princeton University and a B.S. in Biology from St. Joseph’s University. |
| Williams, Nicole | Ms. Nicole S. Williams serves as Director of Orchid Cellmark Inc. since 2002. Ms. Williams formerly was the Chief Financial Officer of Abraxis Bioscience Inc., a biopharmaceutical company, and President of Abraxis Pharmaceutical Products, a division of Abraxis Bioscience Inc., positions she assumed upon the merger of American Pharmaceutical Partners, Inc. and American Bioscience Inc. in April 2006. From 2002 to 2006, Ms. Williams was the Executive Vice President and Chief Financial Officer of American Pharmaceutical Partners and in December 2005, assumed additional responsibilities as President of American Pharmaceutical Partners. Ms. Williams is the President of the Nicklin Capital Group, Inc., a firm she founded in 1999 to invest in and provide consulting to early stage technology companies in the Midwest. From 1992 to 1999, Ms. Williams was the Executive Vice President, Chief Financial Officer and Corporate Secretary of R.P. Scherer Corporation in Troy, Michigan. She currently serves as a director of Progenics Pharmaceuticals, Inc. and Intercept Pharmaceuticals, Inc. Ms. Williams received her Demi-License es Science Politique from the University of Geneva, Switzerland, her License es Science Politique from the Graduate Institute of International Affairs, University of Geneva, Switzerland and her M.B.A. from the Graduate School of Business, University of Chicago. |
| Hart, James | Dr. James M. Hart has been appointed as Director of Orchid Cellmark Inc. effective January 1, 2010. Dr. Hart is the former Commissioner of the City of London Police Force with a career spanning almost four decades in various U.K police forces. His experience included senior operational and command positions at the Metropolitan Police, New Scotland Yard and the Surrey Police force. He also was Chairman of the Association of Chief Police Officers Economic Crime Portfolio, headed the Commissioner's Policy Unit at New Scotland Yard and was a member of the senior team that implemented the restructuring of the Metropolitan Police Force, the U.K.'s largest law enforcement agency. Dr. Hart holds a B.Sc. (Hons) degree in Systems Science and Management, and a Ph.D. degree in Systems Science, both from the City University, London, and is a Fellow of the Chartered Management Institute. He was awarded the Queen's Police Medal in the 1999 Queen's Birthday Honors list and the CBE (Commander of the Order of the British Empire) in 2006. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Beery, James | -- |
| Bologna, Thomas | 1,211,820 |
| Smith, James | 335,467 |
| Thomas, William | 315,565 |
| Boschwitz, Jeffrey | 160,513 |
| Hecht, Sidney | -- |
| Noonan, Kenneth | -- |
| Williams, Nicole | -- |
| Hart, James | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Beery, James | 0 | 0 |
| Bologna, Thomas | 0 | 0 |
| Smith, James | 0 | 0 |
| Thomas, William | 0 | 0 |
| Boschwitz, Jeffrey | 0 | 0 |
| Hecht, Sidney | 0 | 0 |
| Noonan, Kenneth | 0 | 0 |
| Williams, Nicole | 0 | 0 |
| Hart, James | 0 | 0 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
